An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Forced-Titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension.

Trial Profile

An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Forced-Titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2011

At a glance

  • Drugs Aliskiren; Hydrochlorothiazide
  • Indications Isolated systolic hypertension
  • Focus Therapeutic Use
  • Acronyms AIMS
  • Most Recent Events

    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
    • 06 Jan 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 06 Jan 2010 Actual patient number (532) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top